Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock

Fcgamma receptor expression on monocytes and association with etanercept efficacy in rheumatoid arthritis: a prospective cohort study.

Abstract

Background: To investigate whether Fcgamma receptors (FcgammaRs) expression on peripheral blood monocytes predicts clinical response to etanercept in rheumatoid arthritis (RA). Methods: In this prospective cohort study, FcgammaRs expression on peripheral blood monocyte subsets was analyzed by flow cytometry. The primary outcome was the change in DAS28-CRP from baseline to week 12. The secondary outcome was the change in DAS28-ESR. Results: Following etanercept therapy, the proportion of FcgammaRI-positive monocytes and classical (CD14++CD16-) monocytes was reduced, while the proportion of non-classical (CD14+CD16++) monocytes was increased. Changes in intermediate monocytes (CD14++CD16+) were positively correlated with both DAS28-CRP change and DAS28-ESR change at week 24 after etanercept therapy. Patients with high intermediate (CD14++CD16+) monocytes showed significantly greater reductions in DAS28-CRP at week 12. Conclusion: Intermediate monocytes (CD14++CD16+) were correlated with improvements in DAS28-CRP achieved by week 12 following etanercept therapy. RA patients with low intermediate monocytes may derive less benefit from etanercept treatment.